NCT02138929 is a Phase 1 clinical trial of Everolimus in Esophageal Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT02138929?

NCT02138929 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02138929?

Interventions in NCT02138929: Everolimus, LDE 225.

What condition does NCT02138929 study?

NCT02138929 studies Esophageal Cancer.

Is NCT02138929 still recruiting?

NCT02138929 is currently completed. Last updated 11 June 2020.

Last reviewed 2020-06-11 · How we verify

NCT02138929

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

Completed Phase 1 Last updated 11 June 2020

What this trial tests

Phase 1 trial testing Everolimus in Esophageal Cancer in 25 participants. Completed in 8 June 2020.

Timeline

10 November 2014

Primary endpoint
8 June 2020

8 June 2020

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	10 November 2014
Primary completion	8 June 2020
Estimated completion	8 June 2020
Sites	1 location across United States

Drugs / interventions tested

Everolimus (everolimus) — full drug profile →
LDE 225 — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer. The safety of the drug combination will also be studied.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.
Rimkus TK, Carpenter RL, Qasem S, Chan M, et al · · 2016 · cited 411× · PMID 26891329 · DOI 10.3390/cancers8020022
The tumor microenvironment in esophageal cancer.
Lin EW, Karakasheva TA, Hicks PD, Bass AJ, et al · · 2016 · cited 245× · PMID 26923327 · DOI 10.1038/onc.2016.34
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Carpenter RL, Ray H. · · 2019 · cited 77× · PMID 30649745 · DOI 10.1007/s40264-018-0777-5
Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.
Jain S, Song R, Xie J. · · 2017 · cited 72× · PMID 28352196 · DOI 10.2147/ott.s130910
Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer.
Xie H, Paradise BD, Ma WW, Fernandez-Zapico ME. · · 2019 · cited 61× · PMID 31035664 · DOI 10.3390/cells8050394
Signaling pathways in the regulation of cancer stem cells and associated targeted therapy.
Manni W, Min W. · · 2022 · cited 52× · PMID 36226253 · DOI 10.1002/mco2.176
Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives.
Girardi D, Barrichello A, Fernandes G, Pereira A. · · 2019 · cited 52× · PMID 30759860 · DOI 10.3390/cells8020153
The role of Hedgehog and Notch signaling pathway in cancer.
Xia R, Xu M, Yang J, Ma X. · · 2022 · cited 39× · PMID 36517618 · DOI 10.1186/s43556-022-00099-8

Verify or expand the search:

Other trials of Everolimus

Trials testing the same drug.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02138929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 11 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02138929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing